Daiichi Sankyo Company Limited

MUNICH, December 14, 2011 - Pooled results of theSTARS E-III and STARS J-V studies presented at the2011American Society of Hematology (ASH)Annual Meeting Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced the results of a pooled analysis showing that edoxaban*, a direct oral once-daily factor Xa inhibitor, significantly reduced the risk of developing venous thromboembolism (VTE) following total knee or hip arthroplasty when compared to enoxaparin.[1] Patients receiving edoxaban had a lower incidence of a composite of deep vein thrombosis (DVT) and pulmonary embolism (PE) than those treated with enoxaparin (5.1% vs.

TOKYO, July 19, 2011 - -- First Direct Oral Factor Xa Inhibitor Available to Japanese Patients -- Building on its cardiovascular portfolio, Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo), is proud to announce the launch of LIXIANA (JAN: Edoxaban Tosilate Hydrate, INN: edoxaban) in Japan.

TOKYO, April 22, 2011 - Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo), announced today that the company has received its first marketing approval for LIXIANA(R) (JAN: Edoxaban Tosilate Hydrate, INN:edoxaban) 15 mg and 30 mg tablets, by the Ministry of Health, Labor and Welfare in Japan.

TOKYO, December 8, 2010 - Daiichi Sankyo Company, Limited announced that its investigational once-daily oral, direct factor Xa inhibitor, edoxaban, was shown to be superior to enoxaparin sodium in preventing venous thromboembolic (VTE) events in patients following total hip replacement (THR), a type of major orthopedic surgery.

TOKYO, July 12, 2010 - Daiichi Sankyo Company, Limited announced that its investigational once-daily oral, direct factor Xa inhibitor, edoxaban, was shown to be superior to enoxaparin in preventing venous thromboembolic (VTE) events in patients following total knee replacement (TKR), a type of major orthopedic surgery.